

FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

DICTIONARY FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "IMIQUIMOD"/CN 25

E1	1	IMIPROTHRIN-CYPERMETHRIN MIXT./CN
E2	1	IMIPROTHRIN-THIAMETHOXAM MIXT./CN
E3	1 -->	IMIQUIMOD/CN
E4	1	IMIQUIMOD HYDROCHLORIDE/CN
E5	1	IMIRESTAT/CN
E6	1	IMISOPASEM MANGANESE/CN
E7	1	IMITEC X 902/CN
E8	1	IMITECH 201A/CN
E9	1	IMITERITE/CN
E10	1	IMITERITE (HGAG2S2)/CN
E11	1	IMITREX/CN
E12	1	IMITRIN 1/CN
E13	1	IMITRIN 10/CN
E14	1	IMITRIN 11/CN
E15	1	IMITRIN 12/CN
E16	1	IMITRIN 13/CN
E17	1	IMITRIN 14/CN
E18	1	IMITRIN 15/CN
E19	1	IMITRIN 16/CN
E20	1	IMITRIN 17/CN

E21	1	IMITRIN 18/CN
E22	1	IMITRIN 19/CN
E23	1	IMITRIN 2/CN
E24	1	IMITRIN 23/CN
E25	1	IMITRIN 24/CN

=> S E3

L1 1 IMIQUIMOD/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

5.20

5.41

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Mar 2006 VOL 144 ISS 13

FILE LAST UPDATED: 22 Mar 2006 (20060322/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1

L2 310 L1

=> s basal cell carcinom?

155804 BASAL

29 BASALS

155819 BASAL

(BASAL OR BASALS)

2033479 CELL

1784894 CELLS

2696590 CELL

(CELL OR CELLS)

148999 CARCINOM?

L3 1666 BASAL CELL CARCINOM?

(BASAL (W) CELL (W) CARCINOM?)

=> s 13 (L) 12

L4 14 L3 (L) L2

=> s 13 and 12

L5 36 L3 AND L2

=> s cycle or schedule or regimen?

322318 CYCLE

120559 CYCLES

410438 CYCLE

(CYCLE OR CYCLES)

21263 SCHEDULE
8460 SCHEDULES
27357 SCHEDULE
(SCHEDULE OR SCHEDULES)

43190 REGIMEN?
L6 472666 CYCLE OR SCHEDULE OR REGIMEN?

=> s 16 and 14
L7 3 L6 AND L4

=> d ibib 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:802538 CAPLUS
DOCUMENT NUMBER: 141:254555
TITLE: Treatment for basal cell carcinoma
INVENTOR(S): Owens, Mary L.; Fox, Terrance L.; Ginkel, Angela M.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004192585	A1	20040930	US 2004-808004	20040324
PRIORITY APPLN. INFO.:			US 2003-457265P	P 20030325

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.; Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003), 149(66), 53-56
CODEN: BJDSA9; ISSN: 0366-077X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:780706 CAPLUS
DOCUMENT NUMBER: 137:288669
TITLE: Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens
AUTHOR(S): Shumack, Stephen; Robinson, June; Kossard, Steven; Golitz, Loren; Greenway, Hubert; Schroeter, Arnold; Andres, Kara; Amies, Mark; Owens, Mary
CORPORATE SOURCE: Australia
SOURCE: Archives of Dermatology (2002), 138(9), 1165-1171
CODEN: ARDEAC; ISSN: 0003-987X
PUBLISHER: American Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the
treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.;
Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital
Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003),
149(66), 53-56
CODEN: BJDSA9; ISSN: 0366-077X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Basal cell carcinoma (BCC) is a subtype of nonmelanoma skin
cancer (NMSC), with an increasing incidence worldwide. Currently,
excision of the tumor with histol. control is the standard therapy. However,
high incidence rates have led to concern about the economic burden imposed
by BCC management in many countries. Imiquimod is a member of a novel
class of immune response modifiers (IRM), which works by using the
toll-like receptor (TLR)-7. Although the exact mode of action is so far
unknown, it is suggested to induce the expression of different cytokines
like interleukin (IL)-1, IL-6, IL-12, interferon (IFN)- α and tumor
necrosis factor (TNF)- α , which stimulate or enhance both the innate
immune system and the cell-mediated immune response. Preclin. studies
have indicated the potential of this TLR-7 agonist for the treatment of
precancers and tumors in humans. A number of Phase II trials have
demonstrated the efficacy of imiquimod for the treatment of BCC, although
the most appropriate dosing regimen is being confirmed in Phase
III studies. Imiquimod 5% cream for the treatment of mainly superficial
BCC appears to be an effective and well-tolerated treatment option.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006)

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006
E "IMIQUIMOD"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006

L2 310 S L1
L3 1666 S BASAL CELL CARCINOM?
L4 14 S L3 (L) L2
L5 36 S L3 AND L2
L6 472666 S CYCLE OR SCHEDULE OR REGIMEN?
L7 3 S L6 AND L4

=> s 16 and 15

L8 3 L6 AND L5

=> s immune response modifier

192431 IMMUNE
6 IMMUNES
192433 IMMUNE
(IMMUNE OR IMMUNES)
1520221 RESPONSE

318445 RESPONSES
1669651 RESPONSE
(RESPONSE OR RESPONSES)
36656 MODIFIER
26340 MODIFIERS
53132 MODIFIER
(MODIFIER OR MODIFIERS)
L9 199 IMMUNE RESPONSE MODIFIER
(IMMUNE(W) RESPONSE(W) MODIFIER)

=> s 19 (1) 13
L10 20 L9 (L) L3

=> s 110 and 16
L11 1 L10 AND L6

=> d ibib

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:63952 CAPLUS
DOCUMENT NUMBER: 140:121944
TITLE: The use of toll-like receptor-7 agonist in the
treatment of basal cell carcinoma: an overview
AUTHOR(S): Stockfleth, E.; Trefzer, U.; Garcia-Bartels, C.;
Wegner, T.; Schmook, T.; Sterry, W.
CORPORATE SOURCE: Department of Dermatology, University Hospital
Charite, Berlin, D-10117, Germany
SOURCE: British Journal of Dermatology, Supplement (2003),
149(66), 53-56
CODEN: BJDSA9; ISSN: 0366-077X
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 19 and 13
L12 21 L9 AND L3

=> file medline
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
27.15	32.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.75	-0.75

CA SUBSCRIBER PRICE

FILE 'MEDLINE' ENTERED AT 10:18:58 ON 23 MAR 2006

FILE LAST UPDATED: 22 MAR 2006 (20060322/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details
on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s imiquimod

L13 677 IMIQUIMOD

=> s basal cell carcinom?

175166 BASAL

11 BASALS

175172 BASAL

(BASAL OR BASALS)

1990536 CELL

1798779 CELLS

2651453 CELL

(CELL OR CELLS)

419161 CARCINOM?

L14 5638 BASAL CELL CARCINOM?

(BASAL (W) CELL (W) CARCINOM?)

=> s l14 and l13

L15 106 L14 AND L13

=> s cycle or schedule or regimen?

207732 CYCLE

55037 CYCLES

244615 CYCLE

(CYCLE OR CYCLES)

96893 SCHEDULE

20459 SCHEDULES

111322 SCHEDULE

(SCHEDULE OR SCHEDULES)

105335 REGIMEN?

L16 434542 CYCLE OR SCHEDULE OR REGIMEN?

=> s l16 and l15

L17 20 L16 AND L15

=> s l17 not py>2003

1354725 PY>2003

(PY>20039999)

L18 14 L17 NOT PY>2003

=> s l18 not py>2002

1924696 PY>2002

(PY>20029999)

L19 9 L18 NOT PY>2002

=> d ibib 1-9

L19 ANSWER 1 OF 9 MEDLINE on STN

ACCESSION NUMBER: 2002697990 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12459530

TITLE: Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.

AUTHOR: Stockfleth Eggert; Ulrich Claas; Hauschild Axel; Lischner Stephan; Meyer Thomas; Christophers Enno

CORPORATE SOURCE: Department of Dermatology of the Charite, Humboldt University, Schumannstra e 20/21, 10117 Berlin, Germany.. E.Stockfleth@web.de

SOURCE: European journal of dermatology : EJD, (2002 Nov-Dec) Vol. 12, No. 6, pp. 569-72.
Journal code: 9206420. ISSN: 1167-1122.

PUB. COUNTRY: France
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20021217
Last Updated on STN: 20030328
Entered Medline: 20030327

L19 ANSWER 2 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002692165 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12452875
TITLE: Imiquimod 5% cream for the treatment of . .
superficial and nodular basal cell
carcinoma: randomized studies comparing
low-frequency dosing with and without occlusion.

AUTHOR: Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen M R T M

CORPORATE SOURCE: Department of Dermatology, University Hospital Charite,
Humboldt University, Schumannstrasse 20-21, D-10117 Berlin,
Germany.

SOURCE: The British journal of dermatology, (2002 Dec) Vol. 147,
No. 6, pp. 1227-36.
Journal code: 0004041. ISSN: 0007-0963.

PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200302
ENTRY DATE: Entered STN: 20021214
Last Updated on STN: 20030214
Entered Medline: 20030213

L19 ANSWER 3 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002466008 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12224977
TITLE: Efficacy of topical 5% imiquimod cream for the
treatment of nodular basal cell
carcinoma: comparison of dosing regimens.

AUTHOR: Shumack Stephen; Robinson June; Kossard Steven; Golitz Loren; Greenway Hubert; Schroeter Arnold; Andres Kara; Amies Mark; Owens Mary

CORPORATE SOURCE: St George Dermatology and Skin Cancer Center, Level 3, 22
Belgrave St, Kogarah, Australia 2217.. sshumack@bigpond.com

SOURCE: Archives of dermatology, (2002 Sep) Vol. 138, No. 9, pp. 1165-71.
Journal code: 0372433. ISSN: 0003-987X.

PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200210
ENTRY DATE: Entered STN: 20020913
Last Updated on STN: 20021017

Entered Medline: 20021016

L19 ANSWER 4 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002438913 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12196749
TITLE: Imiquimod 5% cream for the treatment of
superficial basal cell
carcinoma: a double-blind, randomized,
vehicle-controlled study.
AUTHOR: Geisse John K; Rich Phoebe; Pandya Amit; Gross Kenneth;
Andres Kara; Ginkel Angie; Owens Mary
CORPORATE SOURCE: Solano Dermatology Associates, Vallejo, California 94589,
USA.
SOURCE: Journal of the American Academy of Dermatology, (2002 Sep)
Vol. 47, No. 3, pp. 390-8.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200209
ENTRY DATE: Entered STN: 20020829
Last Updated on STN: 20020924
Entered Medline: 20020923

L19 ANSWER 5 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002336805 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12079221
TITLE: Epithelial malignancies in organ transplant patients:
clinical presentation and new methods of treatment.
AUTHOR: Stockfleth E; Ulrich C; Meyer T; Christophers E
CORPORATE SOURCE: Department of Dermatology, Christian Albrechts University,
Kiel, Germany.
SOURCE: Recent results in cancer research. Fortschritte der
Krebsforschung. Progres dans les recherches sur le cancer,
(2002) Vol. 160, pp. 251-8.
Journal code: 0044671. ISSN: 0080-0015.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200212
ENTRY DATE: Entered STN: 20020625
Last Updated on STN: 20021217
Entered Medline: 20021212

L19 ANSWER 6 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2002229610 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11966794
TITLE: Treatment of a large superficial basal
cell carcinoma with 5% imiquimod
: a case report and review of the literature.
AUTHOR: Chen T Minsue; Rosen Ted; Orengo Ida
CORPORATE SOURCE: Baylor College of Medicine, Houston, Texas, USA.
SOURCE: Dermatologic surgery : official publication for American
Society for Dermatologic Surgery [et al.], (2002 Apr) Vol.
28, No. 4, pp. 344-6. Ref: 13
Journal code: 9504371. ISSN: 1076-0512.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200205
ENTRY DATE: Entered STN: 20020423
Last Updated on STN: 20020510
Entered Medline: 20020509

L19 ANSWER 7 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2001222213 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11312429
TITLE: Imiquimod 5% cream in the treatment of
superficial basal cell
carcinoma: results of a multicenter 6-week
dose-response trial.
AUTHOR: Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox T L;
Owens M L
CORPORATE SOURCE: Department of Dermatology, St Vincent's Hospital Melbourne
and the Skin & Cancer Foundation, Victoria, Australia:
(Australasian Multicentre Trial Group).
SOURCE: Journal of the American Academy of Dermatology, (2001 May)
Vol. 44, No. 5, pp. 807-13.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200105
ENTRY DATE: Entered STN: 20010529
Last Updated on STN: 20030403
Entered Medline: 20010524

L19 ANSWER 8 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2000040341 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10570388
TITLE: Therapeutic response of basal cell
carcinoma to the immune response modifier
imiquimod 5% cream.
AUTHOR: Beutner K R; Geisse J K; Helman D; Fox T L; Ginkel A; Owens
M L
CORPORATE SOURCE: Department of Dermatology, University of California, San
Francisco, the Department of Medicine, Sutter Solano
Medical Center, Vallejo, Solano Dermatology Associates,
Vallejo, CA, USA.
SOURCE: Journal of the American Academy of Dermatology, (1999 Dec)
Vol. 41, No. 6, pp. 1002-7.
Journal code: 7907132. ISSN: 0190-9622.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199912
ENTRY DATE: Entered STN: 20000113
Last Updated on STN: 20020405
Entered Medline: 19991215

L19 ANSWER 9 OF 9 MEDLINE on STN
ACCESSION NUMBER: 1999370938 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10442350
TITLE: Nonsurgical therapy holds promise for basal

AUTHOR: cell carcinoma.
 SOURCE: Anonymous
 Oncology (Williston Park, N.Y.), (1999 Jul) Vol. 13, No. 7,
 pp. 1044.
 Journal code: 8712059. ISSN: 0890-9091.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: News Announcement
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199909
 ENTRY DATE: Entered STN: 19991012
 Last Updated on STN: 19991012
 Entered Medline: 19990927

=> d ibib abs kwic 9

L19 ANSWER 9 OF 9 MEDLINE on STN
 ACCESSION NUMBER: 1999370938 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 10442350
 TITLE: Nonsurgical therapy holds promise for basal
 cell carcinoma.
 AUTHOR: Anonymous
 SOURCE: Oncology (Williston Park, N.Y.), (1999 Jul) Vol. 13, No. 7,
 pp. 1044.
 Journal code: 8712059. ISSN: 0890-9091.
 PUB. COUNTRY: United States
 DOCUMENT TYPE: News Announcement
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199909
 ENTRY DATE: Entered STN: 19991012
 Last Updated on STN: 19991012
 Entered Medline: 19990927

TI Nonsurgical therapy holds promise for basal cell carcinoma.

CT . . . DT, drug therapy
 Carcinoma, Basal Cell: ME, metabolism
 Carcinoma, Basal Cell: PA, pathology
 Cytokines: BI, biosynthesis
 Cytokines: DE, drug effects
 Drug Administration Schedule
 Humans
 Interferons
 Ointments
 *Skin Neoplasms: DT, drug therapy
 Skin Neoplasms: ME, metabolism
 Skin Neoplasms: PA, pathology
 Treatment. . .

RN 9008-11-1 (Interferons); 99011-02-6 (imiquimod)

=> file pctfull
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
2.87	35.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.75

FILE 'PCTFULL' ENTERED AT 10:21:02 ON 23 MAR 2006
 COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 21 MAR 2006 <20060321/UPTX>

MOST RECENT UPDATE WEEK: 200611
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION

>>> UPDATING OF BIBLIOGRAPHIC DATA DELAYED DUE TO DELIVERY
FORMAT CHANGES <<<

>>> FULL-TEXT UPDATES CONTINUE. PATENT NUMBER AVAILABLE FOR DISPLAY
ONLY, USE FIELD CODE FPI <<<

>>> SDI SEARCHES (ALERTS) WILL BE RESUMED WHEN BIBLIOGRAPHIC DATA
BECOME AVAILABLE <<<

=> s imiquimod

L20 485 IMIQUIMOD

=> s immune response modifier

59832 IMMUNE

2164 IMMUNES

60391 IMMUNE

(IMMUNE OR IMMUNES)

266061 RESPONSE

67030 RESPONSES

272892 RESPONSE

(RESPONSE OR RESPONSES)

33691 MODIFIER

19319 MODIFIERS

46911 MODIFIER

(MODIFIER OR MODIFIERS)

L21 231 IMMUNE RESPONSE MODIFIER

(IMMUNE(W) RESPONSE(W) MODIFIER)

=> s basal cell carcinom?

23035 BASAL

12 BASALS

23039 BASAL

(BASAL OR BASALS)

214988 CELL

186206 CELLS

244057 CELL

(CELL OR CELLS)

30202 CARCINOM?

L22 2869 BASAL CELL CARCINOM?

(BASAL(W) CELL(W) CARCINOM?)

=> s l21/ab

5894 IMMUNE/AB

1643 IMMUNES/AB

6903 IMMUNE/AB

((IMMUNE OR IMMUNES)/AB)

30371 RESPONSE/AB

2596 RESPONSES/AB

32080 RESPONSE/AB

((RESPONSE OR RESPONSES)/AB)

13453 MODIFIER/AB

474 MODIFIERS/AB

13820 MODIFIER/AB

((MODIFIER OR MODIFIERS)/AB)

L23 37 (IMMUNE RESPONSE MODIFIER/AB)

((IMMUNE(W) RESPONSE(W) MODIFIER)/AB)

=> s 123 and 122
L24 28 L23 AND L22

=> s 124 not py>2002
347751 PY>2002
L25 12 L24 NOT PY>2002

=> s cycle or schedule or regimen?
158825 CYCLE
90290 CYCLES
189675 CYCLE
(CYCLE OR CYCLES)
28237 SCHEDULE
11884 SCHEDULES
33594 SCHEDULE
(SCHEDULE OR SCHEDULES)
36444 REGIMEN?
L26 224802 CYCLE OR SCHEDULE OR REGIMEN?

=> s 126 and 125
L27 11 L26 AND L25

=> s 127 and 123
L28 11 L27 AND L23

=> s 128 and 120
L29 5 L28 AND L20

=> d ibib 1-5

L29 ANSWER 1 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002046192 PCTFULL ED 20020624 EW 200224
TITLE (ENGLISH): THIOETHER SUBSTITUTED IMIDAZOQUINOLINES
TITLE (FRENCH): IMIDAZOQUINOLINES A SUBSTITUTION THIOETHER
INVENTOR(S): DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US];
MERRILL, Bryon A., North 8280 1155th Street, River
Falls, WI 54022, US [US, US];
RADMER, Matthew R., 3524 McNair Drive North,
Robbinsdale, MN 55422, US [US, US]
PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
Office Box 33427, Saint Paul, MN 55133-3427, US [US,
US], for all designates States except US;
DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US], for US only;
MERRILL, Bryon A., North 8280 1155th Street, River
Falls, WI 54022, US [US, US], for US only;
RADMER, Matthew R., 3524 McNair Drive North,
Robbinsdale, MN 55422, US [US, US], for US only
AGENT: HOWARD, MarySusan\$, Office of Intellectual Property
Counsel, Post Office Box 33427, Saint Paul, MN
55133-3427\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002046192	A2	20020613

DESIGNATED STATES
W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK

RW (ARIPO): SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
RW (EAPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EPO): AM AZ BY KG KZ MD RU TJ TM
AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US46697 A 20011206
PRIORITY INFO.: US 2000-60/254,218 20001208

L29 ANSWER 2 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002046189 PCTFULL ED 20020624 EW 200224
TITLE (ENGLISH): ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES
TITLE (FRENCH): IMIDAZOQUINOLINES' SUBSTITUEES ARYL ETHER
INVENTOR(S): CHARLES, Leslie J., 787 Larsen Lane, Hudson, WI 54016,
US [US, US];
DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US];
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US];
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US];
MICKELSON, John W., 60887 Valley View Boulevard,
Mattawan, MI 49071, US [US, US]
PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
Office Box 33427, Saint Paul, MN 55133-3427, US [US,
US], for all designates States except US;
CHARLES, Leslie J., 787 Larsen Lane, Hudson, WI 54016,
US [US, US], for US only;
DELLARIA, Joseph F., 10423 Kilbirnie Road, Woodbury, MN
55129, US [US, US], for US only;
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US], for US only;
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US], for US only;
MICKELSON, John W., 60887 Valley View Boulevard,
Mattawan, MI 49071, US [US, US], for US only
AGENT: HOWARD, Mary Susan\$, Office of Intellectual Property
Counsel, Post Office Box 33427, Saint Paul, MN
55133-3427\$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002046189	A2	20020613

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID
IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD
MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2001-US46581 A 20011206
PRIORITY INFO.: US 2000-60/254,218 20001208

L29 ANSWER 3 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002046188 PCTFULL ED 20020624 EW 200224
TITLE (ENGLISH): AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES
TITLE (FRENCH): IMIDAZOQUINOLINES A SUBSTITUTION AMIDO ETHER
INVENTOR(S): CROOKS, Stephen L., 82 Pine Street, Mahtomedi, MN

PATENT ASSIGNEE(S): 55115-1937, US [US, US];
GRIESGRABER, George W., 631 Crimson Leaf Court, Eagan,
MN 55123, US [US, US];
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US];
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US]
3M INNOVATIVE PROPERTIES COMPANY, 3M Center, Post
Office Box 33427, Saint Paul, MN 55133-3427, US [US,
US], for all designates States except US;
CROOKS, Stephen L., 82 Pine Street, Mahtomedi, MN
55115-1937, US [US, US], for US only;
GRIESGRABER, George W., 631 Crimson Leaf Court, Eagan,
MN 55123, US [US, US], for US only;
HEPPNER, Philip D., 607D Woodduck Drive, Woodbury, MN
55125, US [US, US], for US only;
MERRILL, Bryon A., 8280 1155th Street North, River
Falls, WI 54022, US [US, US], for US only
AGENT: HOWARD, MarySusan\$, Office of Intellectual Property
Counsel, Post Office Box 33427, Saint Paul, MN
55133-3427\$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2002046188	A2	20020613
W:	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW		
RW (ARIPO):	GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW		
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM		
RW (EPO):	AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR		
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG		
APPLICATION INFO.:	WO 2001-US46359	A	20011206
PRIORITY INFO.:	US 2000-60/254,218		20001208

L29 ANSWER 4 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000040228 PCTFULL ED 20020515
TITLE (ENGLISH): FORMULATIONS AND METHODS FOR TREATMENT OF MUCOSAL
ASSOCIATED CONDITIONS WITH AN IMMUNE RESPONSE MODIFIER
TITLE (FRENCH): FORMULATIONS ET PROCEDES UTILISES POUR LE TRAITEMENT
DES ETATS PATHOLOGIQUES DES MUQUEUSES AU MOYEN D'UN
MODIFICATEUR DE LA REPONSE IMMUNITAIRE
INVENTOR(S): PHARES, Kenneth;
LI, Jane, Z.;
JOZWIAKOWSKI, Michael, J.;
MILLER, Richard, L.;
SKWIERCZYNSKI, Raymond, D.;
BUSCH, Terri, F.
PATENT ASSIGNEE(S): 3M INNOVATIVE PROPERTIES COMPANY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2000040228	A2	20000713
W:	AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE		

KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB
GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML
MR NE SN TD TG

APPLICATION INFO.: WO 2000-US370 A 20000107
PRIORITY INFO.: US 1999-60/115,253 19990108

L29 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998017279 PCTFULL ED 20020514
TITLE (ENGLISH): IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2
MEDIATED AND RELATED DISEASES
TITLE (FRENCH): COMPOSES MODIFICATEURS DE LA REPOSE IMMUNITAIRE POUR
LE TRAITEMENT DES MALADIES INDUITES PAR LES TH2 OU
ASSOCIEES
INVENTOR(S): TOMAI, Mark, A.;
HAMMERBECK, David, M.;
SWINGLE, Karl, F.
PATENT ASSIGNEE(S): MINNESOTA MINING AND MANUFACTURING COMPANY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9817279	A1	19980430

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW
SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US19990 A 19971024
PRIORITY INFO.: US 1996-60/029,301 19961025
US 1997-60/045,331 19970501

=> d ibib kwic 5

L29 ANSWER 5 OF 5 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998017279 PCTFULL ED 20020514
TITLE (ENGLISH): IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2
MEDIATED AND RELATED DISEASES
TITLE (FRENCH): COMPOSES MODIFICATEURS DE LA REPOSE IMMUNITAIRE POUR
LE TRAITEMENT DES MALADIES INDUITES PAR LES TH2 OU
ASSOCIEES
INVENTOR(S): TOMAI, Mark, A.;
HAMMERBECK, David, M.;
SWINGLE, Karl, F.
PATENT ASSIGNEE(S): MINNESOTA MINING AND MANUFACTURING COMPANY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9817279	A1	19980430

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW
SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK
ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

	GA GN ML MR NE SN TD TG	
APPLICATION INFO.:	WO 1997-US19990	A 19971024
PRIORITY INFO.:	US 1996-60/029,301	19961025
	US 1997-60/045,331	19970501

ABEN Immune response modifier compounds -
imidazoquinoline amines, imidazopyridine amines, 6,7-fused
cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline
amines - are useful for the
treatment of. . .

DETD. . . immunostimulating, antiviral and
antitumor activities are discussed in detail, and certain specific
diseases are identified as being
susceptible to treatment therewith, including basal
cell carcinoma, eczema, essential
thrombocythaemia, hepatitis B, multiple sclerosis, neoplastic diseases,
psoriasis, rheumatoid
arthritis, type I herpes simplex, type II herpes simplex, and warts. One
of these IRM compounds,
known as imiquimod, has been commercialized in a topical
formulation, Aldara TM, for the treatment
of anogenital warts associated with human papilloma virus.

Particularly preferred IRM compounds include 4-amino
ethoxymethyl-(X, (X-dimethyl-
I H-imidazo[4,5-c]quinoline- I -ethanol and 1-(2-methylpropyl)- I
H-imidazo[4,5-c]quinolin amine
(known as Imiquimod).

The first set of studies evaluate the IRM compound 4-amino
ethoxymethyl-oc,ot-
dimethyl- I H-imidazo[4,5-c]quinoline- I -ethanol for its ability to
inhibit. . . day 0 with 10 pg of ovalbumin (OVA) ip in 1%
alum and then boosted 7 days later with the same regimen.
Fourteen days after boosting animals
were dosed by nebulization for 30 minutes using a 1% OVA solution. This
was repeated on. . .

=> d his

(FILE 'HOME' ENTERED AT 10:15:22 ON 23 MAR 2006)

FILE 'REGISTRY' ENTERED AT 10:15:32 ON 23 MAR 2006

E "IMIQUIMOD"/CN 25

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 10:16:02 ON 23 MAR 2006

L2 310 S L1
L3 1666 S BASAL CELL CARCINOM?
L4 14 S L3 (L) L2
L5 36 S L3 AND L2
L6 472666 S CYCLE OR SCHEDULE OR REGIMEN?
L7 3 S L6 AND L4
L8 3 S L6 AND L5
L9 199 S IMMUNE RESPONSE MODIFIER
L10 20 S L9 (L) L3
L11 1 S L10 AND L6
L12 21 S L9 AND L3

FILE 'MEDLINE' ENTERED AT 10:18:58 ON 23 MAR 2006

L13 677 S IMIQUIMOD
L14 5638 S BASAL CELL CARCINOM?
L15 106 S L14 AND L13
L16 434542 S CYCLE OR SCHEDULE OR REGIMEN?

L17 20 S L16 AND L15
L18 14 S L17 NOT PY>2003
L19 9 S L18 NOT PY>2002

FILE 'PCTFULL' ENTERED AT 10:21:02 ON 23 MAR 2006

L20 485 S IMIQUIMOD
L21 231 S IMMUNE RESPONSE MODIFIER
L22 2869 S BASAL CELL CARCINOM?
L23 37 S L21/AB
L24 28 S L23 AND L22
L25 12 S L24 NOT PY>2002
L26 224802 S CYCLE OR SCHEDULE OR REGIMEN?
L27 11 S L26 AND L25
L28 11 S L27 AND L23
L29 5 S L28 AND L20

=> exit

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
10.66	46.09

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.75

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 10:24:13 ON 23 MAR 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 4 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 5 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 6 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 7 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 8 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 9 JAN 30 Saved answer limit increased
NEWS 10 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA
NEWS 11 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 12 FEB 22 Status of current WO (PCT) information on STN
NEWS 13 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 14 FEB 22 Updates in EPFULL; IPC 8 enhancements added